Home/Filings/4/0001209191-19-002826
4//SEC Filing

Laliberte Kevin 4

Accession 0001209191-19-002826

CIK 0001685071other

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 5:01 PM ET

Size

7.7 KB

Accession

0001209191-19-002826

Insider Transaction Report

Form 4
Period: 2019-01-04
Laliberte Kevin
Sr. VP, Product Development
Transactions
  • Award

    Common Stock

    2019-01-04+7,93714,137 total
  • Award

    Employee Stock Option (right to buy)

    2019-01-04+50,00050,000 total
    Exercise: $8.82Exp: 2029-01-03Common Stock (50,000 underlying)
Footnotes (3)
  • [F1]Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019.
  • [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
  • [F3]25% of the total shares subject to the option shall vest on December 31, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.

Issuer

Dova Pharmaceuticals Inc.

CIK 0001685071

Entity typeother

Related Parties

1
  • filerCIK 0001709417

Filing Metadata

Form type
4
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 5:01 PM ET
Size
7.7 KB